TICKERNOMICS Sign up
Last Update: 2024-03-28 02:09:12
Haleon plc ( HLN ) https://www.haleon.com
8.40USD
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Country:
United Kingdom
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
HLN
5.50%
SPY
32.74%
HLN
0.00%
SPY
92.93%
HLN
0.00%
SPY
224.41%
HLN
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
38808.30
52065.75
6.33
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
27.22
2.84
1.85
9.19
1.23
18.32
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
20.87
61.33
21.17
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
6.50
8.04
0.00
Other Earnings and Cash Flow Stats:
Haleon plc ( HLN ) Net Income TTM ($MM) is 1544.75
Haleon plc ( HLN ) Operating Income TTM ($MM) is 2761.88
Haleon plc ( HLN ) Owners' Earnings Annual ($MM) is 0.00
Haleon plc ( HLN ) Current Price to Owners' Earnings ratio is 0.00
Haleon plc ( HLN ) EBITDA TTM ($MM) is 2822.39
Haleon plc ( HLN ) EBITDA Margin is 21.17%
Capital Allocation:
Haleon plc ( HLN ) has paid 0.10 dividends per share and bought back 2.213084 million shares in the past 12 months
Haleon plc ( HLN ) has increased its debt by 603.31859519247 million USD in the last 12 months
Capital Structure:
Haleon plc ( HLN ) Interest-bearing Debt ($MM) as of last quarter is 13877
Haleon plc ( HLN ) Annual Working Capital Investments ($MM) are 539
Haleon plc ( HLN ) Book Value ($MM) as of last quarter is 20973
Haleon plc ( HLN ) Debt/Capital as of last quarter is 66%
Other Balance Sheet Stats:
Haleon plc ( HLN ) has 620 million in cash on hand as of last quarter
Haleon plc ( HLN ) has 6313 million of liabilities due within 12 months, and long term debt 12304 as of last quarter
Haleon plc ( HLN ) has 4617 common shares outstanding as of last quarter
Haleon plc ( HLN ) has 0 million USD of preferred stock value
Academic Scores:
Haleon plc ( HLN ) Altman Z-Score is 2.65 as of last quarter
Haleon plc ( HLN ) Piotroski Score is 6.00 as of last quarter
Corporate Governance:
Haleon plc ( HLN ) largest shareholder is Aristotle Capital Management LLC owning 8905038 shares at 74.85 ($MM) value
(an insider) shares of Haleon plc ( HLN ) for the amount of $ on
6.41% of Haleon plc ( HLN ) is held by insiders, and 8.12% is held by institutions
Haleon plc ( HLN ) went public on 2022-07-22
Other Haleon plc ( HLN ) financial metrics:
FCF:3884.52
Unlevered Free Cash Flow:978.59
EPS:0.40
Operating Margin:20.87
Gross Profit Margin:61.33
Div. Payout Ratio%:33.55
Div. Growth YoY%:0.00
Equity Return%:5.72
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Haleon plc ( HLN ) :
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands includes Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Weybridge, the United Kingdom.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.